06 August 2019

Minicare: Big Mistake Opens Door For Siemens

CM Life Science By CM Life Science

Last week I posted about Siemens Healthineers’ acquisition of Minicare and it received an incredible reaction.

It’s not surprising really. This deal has it all: a market leader, an exciting product and plenty of controversy.

So, what does it all mean?

First off, I should point out that the Minicare I-20 could be a market leading product with its handheld point-of-care (PoC) system able to exclude or confirm the presence of suspected heart attacks. It’s a product that has so much potential, when in the right hands.

Although Siemens Healthineers’ already has quite a strong PoC system, ’epoc’, this will be a welcome addition and make the company a real force in the PoC space.

Siemens Healthineers’ backing of this technology does not spell good news for competitors like Abbott (iStat) and Quidel (Triage), who now must invest and innovate to remain competitive in the market.

Philips Healthcare won’t be enthused by the news either. Having invested a decade’s worth of research on Minicare’s technology, originally under the name of Magnotech, before parting ways last year because of ‘inadequate business opportunities.’ This lack of faith could prove to be a huge mistake.

Over the last year, Minicare claims to have improved its device even more, reaching a new level of sensitivity and accuracy. If this is true, the device will be able to produce similar levels of performance to heavy-weight hospital equipment with the advantage of being handheld and mobile.

With a new home, the Minicare I-20 will cement its place as the market leader. As always, this extra competition will encourage innovation among competitors. This means that we can look forward to the emergence of exciting new products and improved healthcare in the future.

Back to the top


What's Next for POC Diagnostics?
18 February 2021
By Nathan Sharpe By Nathan Sharpe

What's Next for POC Diagnostics?

Diagnostics still has a crucial role to play in combating COVID-19 and, with new funding, a lot of exciting plans too. To find out more, I spoke to Jonathan O’Halloran, who is CEO at QuantuMDx.

Diagnostics is Changing to Meet Your Demands.
09 February 2021
By Adam Hargreaves By Adam Hargreaves

Diagnostics is Changing to Meet Your Demands.

What do you want from diagnostics? Before COVID-19, this wouldn’t have been a question at the forefront of so many peoples' minds. However, now it is and consumers are demanding changes to the industry.

What Can You Expect from Life Sciences in 2021?
25 January 2021
By Ameer Khan By Andrew Linskey By Ben Paice By Eleanor Doolin By Jack Shute By Matthew Barrows By Paul Atkinson By Ameer Khan & Andrew Linskey & Ben Paice & Eleanor Doolin & Jack Shute & Matthew Barrows & Paul Atkinson

What Can You Expect from Life Sciences in 2021?

There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...

What Does COVID-19 Mean for Life Science M&As?
15 December 2020
By Paul Atkinson By Paul Atkinson

What Does COVID-19 Mean for Life Science M&As?

With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.

Get the latest into your inbox.